Sage Therapeutics, Inc.
Sage Therapeutics, Inc. (SAGE): 7 pipeline candidates · ~19 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
18.6 months
D/E 0.15 · 0% dilution
Lead: Approved
7 candidates
N/A
N/A
A transparent, data-derived signal for Sage Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$68.9M
Quarterly Burn
$58.7M
Runway
18.6 mo
Revenue
$31.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
Frequently asked questions
How many drug candidates are in Sage Therapeutics, Inc.'s pipeline?
Sage Therapeutics, Inc. (SAGE) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Sage Therapeutics, Inc.'s lead drug candidate?
Sage Therapeutics, Inc.'s most advanced tracked candidate is dalzanemdor (Phase 2/Phase 3) for Cognitive impairment associated with Huntington's disease, Parkinson's disease, and Alzheimer's disease.
What is Sage Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Sage Therapeutics, Inc. has approximately 18.6 months of cash runway.
Who is the CEO of Sage Therapeutics, Inc.?
Business Conduct is the chief executive officer of Sage Therapeutics, Inc. (SAGE).
Get the full picture on Sage Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.